-
1 Comment
Taiwan Liposome Company, Ltd is currently in a long term uptrend where the price is trading 27.1% above its 200 day moving average.
From a valuation standpoint, the stock is 94.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 68.1.
Taiwan Liposome Company, Ltd's total revenue rose by 1.1% to $12M since the same quarter in the previous year.
Its net income has dropped by 6.0% to $-293M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.7% to $-207M since the same quarter in the previous year.
Based on the above factors, Taiwan Liposome Company, Ltd gets an overall score of 4/5.
| ISIN | US8740381020 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Beta | 0.8 |
|---|---|
| Market Cap | 303M |
| PE Ratio | None |
| Target Price | 9.25 |
| Dividend Yield | 0.0% |
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III clinical trial for the treatment of knee osteoarthritis pain. The company's product candidates also comprise TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that has completed Phase II clinical trial to treat post-surgical pain; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma; and TLC19 that is in Phase I clinical trial to treat COVID-19.Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TLC using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
